Lead Product(s): LP352
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Arena Pharmaceuticals
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 28, 2020
Proceeds from the financing will be used to support the development of LP352 for treatment-resistant developmental and epileptic encephalopathies, and preclinical programs relating to LP143 and LP659 for the potential treatment of microglial neuroinflammatory diseases.